Listen to Fred Van Goor, Vice President of Cystic Fibrosis Research, talk about our commitment to pursuing new therapeutic advances for all people living with cystic fibrosis and how this commitment drives scientific innovation.

Learn about an essential component in stem cell transplants, known as conditioning regimens. This is just one of the tools in our drug discovery toolbox that could support potential treatments.

Vertex is committed to the sickle cell disease community. Beyond our science, it’s about showing up and locking arms with the community to work together toward meaningful change.

Learn about one of our innovative approaches, cell encapsulation. This is just one of the tools in our drug discovery toolbox that has the potential to treat serious diseases.

Vice President of Clinical Development Dr. Ogo Egbuna shares why it’s important to raise awareness about APOL1-mediated kidney disease (AMKD).

Learn about one of our innovative approaches, CRISPR/Cas9. This is just one of the tools in our drug discovery toolbox that has the potential to unlock new ways to impact genetic diseases.

Mark Higgins, Senior Director of Clinical Development, highlights Vertex’s patient-first approach to clinical trials and discusses his experience discovering potential treatments for people with cystic fibrosis.

Learn why the Vertex Pharmaceuticals approach to career growth is unique from Chief Human Resources Officer Stephanie Franklin.

Looking back on 2022, the Vertex Foundation remains grateful and excited for the future. From supporting healthy families to social innovation and STEAM education, we’re proud of the impact Foundation partners continue to make in our communities around the world. 

Cystic fibrosis is a rare, genetic, progressive disease, in which symptoms and organ damage can manifest very early in life. These may not, however, be outwardly visible in all children and while some children can appear well on the outside, what is happening inside their bodies can tell a different story.